Mohammed Eslam

28.0k total citations · 10 hit papers
123 papers, 9.6k citations indexed

About

Mohammed Eslam is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mohammed Eslam has authored 123 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Epidemiology, 75 papers in Hepatology and 30 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mohammed Eslam's work include Liver Disease Diagnosis and Treatment (106 papers), Hepatitis C virus research (46 papers) and Liver Disease and Transplantation (28 papers). Mohammed Eslam is often cited by papers focused on Liver Disease Diagnosis and Treatment (106 papers), Hepatitis C virus research (46 papers) and Liver Disease and Transplantation (28 papers). Mohammed Eslam collaborates with scholars based in Australia, Egypt and Italy. Mohammed Eslam's co-authors include Elisabetta Bugianesi, Jacob George, Timothy Hardy, Quentin M. Anstee, M. Marietti, Zobair M. Younossi, Linda Henry, Jacob George, Luca Valenti and Stefano Romeo and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Mohammed Eslam

118 papers receiving 9.5k citations

Hit Papers

Global burden of NAFLD and NASH: trends, predictions, ris... 2017 2026 2020 2023 2017 2017 2018 2019 2020 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
    2017 3.9k citations Mohammed Eslam et al. Nature Reviews Gastroenterology & Hepatology profile →
  2. Genetics and epigenetics of NAFLD and NASH: Clinical impact
    2017 692 citations Mohammed Eslam, Luca Valenti et al. Journal of Hepatology profile →
  3. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
    2018 574 citations Vincent Wai‐Sun Wong, Mohammed Eslam et al. profile →
  4. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
    2019 361 citations Mohammed Eslam et al. profile →
  5. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
    2020 285 citations Mohammed Eslam, Jacob George et al. Liver International profile →
  6. The changing epidemiology of liver diseases in the Asia–Pacific region
    2018 242 citations Martin C. S. Wong, Jason L. Huang et al. Nature Reviews Gastroenterology & Hepatology profile →
  7. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
    2019 240 citations Ali Bayoumi, Christopher Liddle et al. profile →
  8. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
    2022 184 citations Mohammed Eslam et al. profile →
  9. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
    2021 163 citations Mohammed Eslam, Jacob George et al. profile →
  10. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
    2022 156 citations Mohammed Eslam, Jacob George et al. Nature Reviews Gastroenterology & Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammed Eslam Australia 37 8.4k 3.9k 3.3k 1.5k 1.2k 123 9.6k
Aaron B. Koenig United States 12 7.8k 0.9× 3.3k 0.9× 3.2k 1.0× 1.4k 1.0× 1.2k 0.9× 15 8.8k
Yousef Fazel United States 6 7.4k 0.9× 3.2k 0.8× 3.0k 0.9× 1.3k 0.9× 1.1k 0.9× 13 8.2k
Mazen Noureddin United States 49 7.1k 0.8× 3.9k 1.0× 2.7k 0.8× 1.3k 0.9× 932 0.7× 272 9.1k
Dinan Abdelatif United States 5 7.0k 0.8× 2.9k 0.8× 2.9k 0.9× 1.2k 0.8× 1.0k 0.8× 10 7.8k
Sven Francque Belgium 48 7.3k 0.9× 3.2k 0.8× 2.9k 0.9× 1.5k 1.0× 801 0.6× 194 9.1k
Silvia Fargion Italy 62 7.3k 0.9× 3.1k 0.8× 2.9k 0.9× 1.6k 1.1× 1.2k 0.9× 267 11.6k
Anna Ludovica Fracanzani Italy 59 6.2k 0.7× 2.6k 0.7× 2.5k 0.8× 1.2k 0.8× 866 0.7× 217 9.4k
Helena Cortez‐Pinto Portugal 45 7.7k 0.9× 3.0k 0.8× 3.1k 0.9× 1.9k 1.3× 2.5k 2.0× 138 10.0k
Yao‐Chang Liu United States 6 7.8k 0.9× 3.4k 0.9× 2.8k 0.9× 1.5k 1.0× 985 0.8× 9 9.1k
Paola Dongiovanni Italy 57 6.5k 0.8× 2.2k 0.6× 2.8k 0.9× 1.5k 1.0× 829 0.7× 188 9.1k

Countries citing papers authored by Mohammed Eslam

Since Specialization
Citations

This map shows the geographic impact of Mohammed Eslam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Eslam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Eslam more than expected).

Fields of papers citing papers by Mohammed Eslam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Eslam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Eslam. The network helps show where Mohammed Eslam may publish in the future.

Co-authorship network of co-authors of Mohammed Eslam

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed Eslam. A scholar is included among the top collaborators of Mohammed Eslam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed Eslam. Mohammed Eslam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alqahtani, Saleh A., et al.. (2025). Energy metabolism: An emerging therapeutic frontier in liver fibrosis. Annals of Hepatology. 30(1). 101896–101896. 1 indexed citations
2.
Alqahtani, Saleh A., Wai‐Kay Seto, Yusuf Yılmaz, et al.. (2025). Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease. Gastroenterology report. 13. goaf044–goaf044.
3.
Pan, Ziyan, Ali Bayoumi, Brian Gloss, et al.. (2024). Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. Science Translational Medicine. 16(741). eadj0133–eadj0133. 15 indexed citations
4.
Tang, Liang‐Jie, Dan‐Qin Sun, Sherlot Juan Song, et al.. (2024). Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International. 44(5). 1129–1141. 4 indexed citations
5.
Rodionov, Roman N., Natalia Jarzebska, Yen Chin Koay, et al.. (2024). Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosis. iScience. 27(12). 111366–111366. 1 indexed citations
6.
Eslam, Mohammed & Jacob George. (2024). MAFLD: from a disease framework to patient care. Hepatology International. 18(S2). 823–826.
7.
Pan, Ziyan, et al.. (2024). A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells. Frontiers in Bioscience-Landmark. 29(4). 148–148. 1 indexed citations
8.
Eslam, Mohammed, et al.. (2023). Molecular Mechanisms Involved in MAFLD in Cholecystectomized Patients: A Cohort Study. Genes. 14(10). 1935–1935. 2 indexed citations
9.
Fischer, Janett, Tobias Müller, R Heyne, et al.. (2023). Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatology Research. 53(12). 1156–1168.
10.
Pan, Ziyan, Brian Gloss, Duncan McLeod, et al.. (2023). Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism. 144. 155583–155583. 23 indexed citations
11.
Bayoumi, Ali, Khaled Thabet, Ziyan Pan, et al.. (2022). A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nature Communications. 13(1). 7430–7430. 29 indexed citations
12.
Fischer, Janett, Tobias Müller, R Heyne, et al.. (2022). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens. 12(1). 54–54. 5 indexed citations
13.
Leeming, Diana Julie, Signe Holm Nielsen, Mette Juul Nielsen, et al.. (2021). Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. SHILAP Revista de lepidopterología. 8(2). HEP32–HEP32. 15 indexed citations
14.
Zhou, Gang, Shuanglin Han, Zhiqiang Zhang, et al.. (2020). An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Letters. 501. 124–132. 54 indexed citations
15.
Eslam, Mohammed, et al.. (2020). Current Aspects of Hepatic Lipotoxicity in Metabolic Associated Fatty Liver Disease. 8(1). 74–84. 1 indexed citations
16.
Terczyńska‐Dyla, Ewa, Karen Louise Thomsen, Jacob George, et al.. (2018). The role of IFN in the development of NAFLD and NASH. Cytokine. 124. 154519–154519. 35 indexed citations
17.
Wong, Martin C. S., Jason L. Huang, Jacob George, et al.. (2018). The changing epidemiology of liver diseases in the Asia–Pacific region. Nature Reviews Gastroenterology & Hepatology. 16(1). 57–73. 242 indexed citations breakdown →
18.
Khattab, Mahmoud, et al.. (2011). 1161 ASSOCIATION OF SERUM ADIPOCYTOKINES WITH LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4. Journal of Hepatology. 54. S458–S459. 3 indexed citations
19.
Khattab, Mahmoud, et al.. (2011). 1160 INSULIN RESISTANCE IN HEPATITIS C GENOTYPE 4 IS PARTIALLY MEDIATED BY VIRUS-SPECIFIC CHANGES IN ADIPOCYTOKINES. Journal of Hepatology. 54. S458–S458. 2 indexed citations
20.
Khattab, Mahmoud, Peter Ferenci, Stephanos J. Hadziyannis, et al.. (2010). Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. Journal of Hepatology. 54(6). 1250–1262. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aaron B. Koenig Breakdown of academic impact, for papers by Yousef Fazel Breakdown of academic impact, for papers by Mazen Noureddin Breakdown of academic impact, for papers by Dinan Abdelatif Breakdown of academic impact, for papers by Sven Francque Breakdown of academic impact, for papers by Silvia Fargion Breakdown of academic impact, for papers by Anna Ludovica Fracanzani Breakdown of academic impact, for papers by Helena Cortez‐Pinto Breakdown of academic impact, for papers by Yao‐Chang Liu Breakdown of academic impact, for papers by Paola Dongiovanni
Rankless by CCL
2026